The role of HIV in serious diseases other than AIDS.
作者信息
Phillips Andrew N, Neaton James, Lundgren Jens D
出版信息
AIDS. 2008 Nov 30;22(18):2409-18. doi: 10.1097/QAD.0b013e3283174636.
Abstract
摘要
相似文献
1
The role of HIV in serious diseases other than AIDS.
AIDS. 2008 Nov 30;22(18):2409-18. doi: 10.1097/QAD.0b013e3283174636.
2
CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection.
AIDS. 2008 Apr 23;22(7):841-8. doi: 10.1097/QAD.0b013e3282f7cb76.
3
Risk of non-AIDS-defining events among HIV-infected patients not yet on antiretroviral therapy.
HIV Med. 2015 May;16(5):265-72. doi: 10.1111/hiv.12202. Epub 2015 Jan 21.
4
Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy.
AIDS. 2000 May 26;14(8):959-69. doi: 10.1097/00002030-200005260-00007.
5
Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma.
AIDS. 2002 Mar 8;16(4):531-6. doi: 10.1097/00002030-200203080-00003.
6
HIV infection, inflammation, immunosenescence, and aging.
Annu Rev Med. 2011;62:141-55. doi: 10.1146/annurev-med-042909-093756.
7
How does HIV impact on non-AIDS events in the era of HAART?
Int J STD AIDS. 2009 Jan;20(1):1-3. doi: 10.1258/ijsa.2008.008302.
8
Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients.
AIDS. 2010 Jul 31;24(12):1877-86. doi: 10.1097/QAD.0b013e32833b1b26.
9
Immune response during HIV and tuberculosis co-infection.
Mem Inst Oswaldo Cruz. 1998 May-Jun;93(3):399-402. doi: 10.1590/s0074-02761998000300023.
10
T cells versus HIV-1: fighting exhaustion as well as escape.
Nat Immunol. 2003 Jan;4(1):12-3. doi: 10.1038/ni0103-12.
引用本文的文献
1
Two-threshold defined immune non-responders are associated with long-term morbidity in people with HIV: a prospective cohort study.
Emerg Microbes Infect. 2025 Dec;14(1):2539198. doi: 10.1080/22221751.2025.2539198. Epub 2025 Aug 8.
2
Prevalence of thyroid dysfunction in highly active antiretroviral therapy -Exposed people living with human immunodeficiency virus.
Thyroid Res. 2025 Jun 10;18(1):24. doi: 10.1186/s13044-025-00240-z.
3
Selected comorbidities and the probability of ART switch in PWH with undetectable HIV-RNA: a retrospective analysis in Italy.
J Antimicrob Chemother. 2025 Jul 1;80(7):1849-1859. doi: 10.1093/jac/dkaf137.
4
HIV-SEQ REVEALS GLOBAL HOST GENE EXPRESSION DIFFERENCES BETWEEN HIV-TRANSCRIBING CELLS FROM VIREMIC AND SUPPRESSED PEOPLE WITH HIV.
bioRxiv. 2024 Dec 20:2024.12.17.629023. doi: 10.1101/2024.12.17.629023.
5
Impact of Chronic HIV Infection on Acute Immune Responses to SARS-CoV-2.
J Acquir Immune Defic Syndr. 2024 May 1;96(1):92-100. doi: 10.1097/QAI.0000000000003399.
6
Investigation of Causal Effects of Protein Biomarkers on Cardiovascular Disease in Persons With HIV.
J Infect Dis. 2023 Apr 18;227(8):951-960. doi: 10.1093/infdis/jiac496.
7
New Assay Reveals Vast Excess of Defective over Intact HIV-1 Transcripts in Antiretroviral Therapy-Suppressed Individuals.
J Virol. 2022 Dec 21;96(24):e0160522. doi: 10.1128/jvi.01605-22. Epub 2022 Nov 30.
8
Human immunodeficiency virus infection and risks of morbidity and death in adults with incident heart failure.
Eur Heart J Open. 2021 Dec 1;1(3):oeab040. doi: 10.1093/ehjopen/oeab040. eCollection 2021 Nov.
9
Healthcare resource utilization and costs associated with renal, bone and cardiovascular comorbidities among persons living with HIV compared to the general population in Quebec, Canada.
PLoS One. 2022 Jul 11;17(7):e0262645. doi: 10.1371/journal.pone.0262645. eCollection 2022.
10
Immune correlates of cardiovascular co-morbidity in HIV infected participants from South India.
BMC Immunol. 2022 May 17;23(1):24. doi: 10.1186/s12865-022-00498-0.
本文引用的文献
1
Earlier initiation of antiretroviral therapy in treatment-naïve patients: implications of results of treatment interruption trials.
Curr Opin HIV AIDS. 2008 Mar;3(2):112-7. doi: 10.1097/COH.0b013e3282f3808b.
2
Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial.
Ann Intern Med. 2008 Sep 2;149(5):289-99. doi: 10.7326/0003-4819-149-5-200809020-00003.
3
Determination of the underlying cause of death in three multicenter international HIV clinical trials.
HIV Clin Trials. 2008 May-Jun;9(3):177-85. doi: 10.1310/hct0903-177.
4
Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial.
Antivir Ther. 2008;13(2):177-87. doi: 10.1177/135965350801300215.
5
Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003.
Ann Intern Med. 2008 May 20;148(10):728-36. doi: 10.7326/0003-4819-148-10-200805200-00005.
6
Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study.
J Infect Dis. 2008 Apr 15;197(8):1133-44. doi: 10.1086/586713.
7
CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection.
AIDS. 2008 Apr 23;22(7):841-8. doi: 10.1097/QAD.0b013e3282f7cb76.
8
Causes of the first AIDS-defining illness and subsequent survival before and after the advent of combined antiretroviral therapy.
HIV Med. 2008 Apr;9(4):246-56. doi: 10.1111/j.1468-1293.2008.00554.x.
9
Risk of hepatitis-related mortality increased among hepatitis C virus/HIV-coinfected drug users compared with drug users infected only with hepatitis C virus: a 20-year prospective study.
J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):221-5. doi: 10.1097/QAI.0b013e31815d2f59.
10
Hepatic inflammatory cytokine mRNA expression in hepatitis C virus-human immunodeficiency virus co-infection.
J Viral Hepat. 2008 May;15(5):331-8. doi: 10.1111/j.1365-2893.2007.00949.x. Epub 2007 Dec 20.
Zotero 插件